Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Darinaparsin + U0126|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Darinaparsin||ZIO-101|ZIO101|ZIO 101|S-Dimethylarsino-Glutathione|DMAIII(SG)||Darinaparsin, is an arsenic containing compound that inhibits signaling via the MAPK and Hedgehog signaling pathways (PMID: 25381261, 25316819), potentially leading to tumor growth inhibition and tumor cell killing (PMID: 25381261, PMID: 25316819, PMID: 30080396).|
|U0126||MEK inhibitor (Pan) 22 MEK1 Inhibitor 20 MEK2 Inhibitor 18||U0126 binds and inhibits Mek1 and Mek2, which may inhibit the activation of downstream signaling targets and reduce tumor cell proliferation (PMID: 9873633).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Hodgkin's lymphoma||not applicable||Darinaparsin + U0126||Preclinical - Cell culture||Actionable||In a preclinical study, Darinaparsin treatment in combination with U0126 inhibited Erk1/2 phosphorylation and led to enhanced apoptosis in Hodgkin's lymphoma cells compared to Darinaparsin treatment alone in culture (PMID: 25316819).||25316819|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|